Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. mflodx

mfloDx SIGNED

Adaptable Multiflow Diagnostic Platform to Genetically Identify Drug Resistant Infection

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 mfloDx project word cloud

Explore the words cloud of the mfloDx project. It provides you a very rough idea of what is the project "mfloDx" about.

income    countries    close    costly    faulty    million    killed    pilot    diagnostics    worldwide    thereby    generation    spreading    organization    96    suffering    inappropriate    market    identification    population    molecular    rapid    curtail    bacteria    health    addressable    thousands    projected    treat    resistant    mdr    undergo    tb    forms    rate    expenditure    grow    euros    specificity    unnecessary    frac14    incorrect    prescription    33    2015    lag    mid    32k    diagnoses    suggest    infects    spread    patients    15    tuberculosis    92    time    afflicted    power    antibiotics    tests    mflodx    2030    treatments    trained    recommended    incomplete    platform    efficiency    urgently    detection    drug    life    2000    tools    global    world    stop    flourishing    showed    diagnostic    prescriptions    estimates    first    billion    tens    people    983    untreatable    months    regimens    infections    six    accurate    commercial    antibiotic    diagnosis    treatment    reduce    hours    recommend    care    appropriate    100    patient    point    strains    times    alarming    2024    tbplus    minimdr    prevent   

Project "mfloDx" data sheet

The following table provides information about the project.

Coordinator		 EMPE DIAGNOSTICS AB 

Organization address
address: KAROLINSKA ISTITUTE SCIENCE PARK NOBELS VAG 16
city: STOCKHOLM
postcode: 171 65
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Sweden [SE]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2020-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    EMPE DIAGNOSTICS AB SE (STOCKHOLM) coordinator 50˙000.00

Map

 Project objective

Tuberculosis (TB) killed 33 million people worldwide in 2000-2015 and infects an estimated ¼ of the world population. Drug-resistant forms of TB are flourishing at an alarming rate due to faulty diagnosis and widespread prescription of incorrect antibiotics. Rapid and accurate detection of multi-drug resistant (MDR) strains is urgently needed to effectively treat patients and prevent spreading of untreatable TB forms. Simple, low cost diagnostic tools are needed to enable point-of-care testing in low- and mid-income countries. mfloDx is a low-cost, simple diagnostic platform that can identify close to 100% of drug resistant TB cases. Pilot tests of the first product, miniMDR-TB, showed the efficiency and specificity to be 92-96% in agreement with that of another molecular test recommended by the World Health Organization. Our next-generation mfloDx products, MDR-TB and MDR-TBplus, are expected to have close to 100% MDR-TB identification power. The low cost of mfloDx tests will enable market uptake in highly afflicted developing countries, and thereby help to stop the loss of life, the spread of antibiotic-resistant infections, and prevent unnecessary costs. Projected global expenditure on diagnosis and treatment of TB will reach €983 billion between 2015-2030. The addressable market for TB diagnostics is projected to grow to €3.1 billion by 2024. Available commercial diagnostics for MDR-TB often deliver incomplete diagnoses and require long lag times, costly equipment (€15-32K), and highly trained personnel to recommend prescriptions. As a result, less than one-third of new TB patients undergo testing to determine appropriate antibiotic treatments. Our estimates suggest that mfloDx would reduce the treatment costs per MDR-TB patient by tens of thousands of euros and diagnosis time from about six months to two hours. This would avoid costly and inappropriate antibiotic regimens, reduce patient suffering, and curtail the spread of drug-resistant bacteria.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MFLODX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MFLODX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More  

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More  

BeatsDigTherapeutics (2019)

Project SCALE: Tailored Digital Therapeutics for Neurological and Brain Disorders

Read More